Elizabeth Elliot, DO
Internal Medicine · Traverse City, MINPI 1013919109
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. GSK accounts for 73.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $378 and has fallen 66.9% since, to $125 in 2024.
Across 46 payments — averaging $30.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Dexcom, Inc.$106
- Lilly USA, LLC$36
- Amgen$34
- Takeda Pharmaceuticals U.S.A., Inc.$30
- Pfizer$27
- plus $140 from 9 others
What the payments were for
- Food & beverage$1,391100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 27 | $1,018 |
| Dexcom, Inc. | 1 | $106 |
| Lilly USA, LLC | 3 | $36 |
| Amgen | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Pfizer | 2 | $27 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| AbbVie | 1 | $20 |
| Novo Nordisk | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
| Merck | 1 | $12 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$365
- AREXVY$245
- DEXCOM G7 GSS (161)$106
How this compares
$1,391 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 262 | $265,796 |
| EliquisApixaban | 152 | $180,048 |
| OzempicSemaglutide | 52 | $75,732 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $75,446 |
| TrulicityDulaglutide | 29 | $38,436 |
| MyrbetriqMirabegron | 40 | $34,187 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $31,249 |
| XareltoRivaroxaban | 21 | $29,373 |
| FarxigaDapagliflozin Propanediol | 19 | $25,606 |
| JanuviaSitagliptin Phosphate | 34 | $24,336 |
| TradjentaLinagliptin | 28 | $24,023 |
| MounjaroTirzepatide | 22 | $22,949 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 281 | $7,297 |
| Losartan Potassium | 418 | $7,060 |
| Levothyroxine Sodium | 488 | $6,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $12 | $289,819290 claims |
| PfizerEliquis, Premarin | $27 | $185,336164 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,018 | $106,695103 claims |
| Novo NordiskOzempic | $18 | $75,73252 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $36 | $61,38551 claims |
| MerckJanuvia | $12 | $24,33634 claims |
| AbbVieSynthroid | $20 | $2,41334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Traverse City
- Steven LamieTraverse City$54K
- Adrienne EdgrenTraverse City$47K
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.